APLS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $14,750,062.16

Apellis Pharmaceuticals Insider Trading History Chart

Apellis Pharmaceuticals Share Price & Price History

^$23.32

▲ +0.49 (2.15%)

As of 02/3/2026 05:00 PM ET

Days: 30 | 90 | 365

Apellis Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/22/2026	Caroline Baumal	Insider	Sell	2,797	$21.77	$60,890.69	86,527
1/22/2026	Cedric Francois	CEO	Sell	27,192	$21.77	$591,969.84	286,045
1/22/2026	David O. Watson	General Counsel	Sell	7,832	$21.77	$170,502.64	88,531
1/22/2026	James George Chopas	CAO	Sell	2,064	$21.77	$44,933.28	49,805
1/22/2026	Mark Jeffrey DeLong	Insider	Sell	3,371	$21.77	$73,386.67	78,353
1/22/2026	Nur Nicholson	Insider	Sell	7,725	$21.77	$168,173.25	71,118
1/22/2026	Pascal Deschatelets	Insider	Sell	5,928	$21.77	$129,052.56	1,151,382
1/22/2026	Timothy Eugene Sullivan	CFO	Sell	10,287	$21.77	$223,947.99	93,901
1/20/2026	Caroline Baumal	Insider	Sell	1,882	$19.79	$37,244.78	89,324
1/20/2026	Cedric Francois	CEO	Sell	8,182	$19.79	$161,921.78	313,237
1/20/2026	David O. Watson	General Counsel	Sell	2,475	$19.79	$48,980.25	96,363
1/20/2026	James George Chopas	CAO	Sell	726	$19.79	$14,367.54	51,869
1/20/2026	Mark Jeffrey DeLong	Insider	Sell	1,334	$19.79	$26,399.86	81,724
1/20/2026	Nur Nicholson	Insider	Sell	2,203	$19.79	$43,597.37	78,843
1/20/2026	Pascal Deschatelets	Insider	Sell	909	$19.79	$17,989.11	1,157,310
1/20/2026	Timothy Eugene Sullivan	CFO	Sell	2,892	$19.79	$57,232.68	104,188
1/13/2026	Cedric Francois	CEO	Sell	10,186	$22.19	$226,027.34	321,419
1/13/2026	David O. Watson	General Counsel	Sell	5,780	$22.19	$128,258.20	98,838
1/13/2026	James George Chopas	CAO	Sell	873	$22.19	$19,371.87	52,595
1/13/2026	Mark Jeffrey DeLong	Insider	Sell	1,780	$22.19	$39,498.20	83,058
1/13/2026	Nur Nicholson	Insider	Sell	2,618	$22.19	$58,093.42	81,046
1/13/2026	Pascal Deschatelets	Insider	Sell	2,277	$22.19	$50,526.63	1,158,219
1/13/2026	Timothy Eugene Sullivan	CFO	Sell	3,856	$22.19	$85,564.64	107,080
12/16/2025	David O. Watson	General Counsel	Sell	5,000	$24.49	$122,450.00	103,730
11/17/2025	David O. Watson	General Counsel	Sell	5,000	$20.06	$100,300.00	108,730
10/21/2025	Timothy Eugene Sullivan	CFO	Sell	10,000	$28.03	$280,300.00	110,936
10/16/2025	David O. Watson	General Counsel	Sell	5,000	$25.22	$126,100.00	113,730
10/10/2025	A. Sinclair Dunlop	Director	Sell	31,092	$23.72	$737,502.24	3,837
9/19/2025	A. Sinclair Dunlop	Director	Sell	31,092	$22.95	$713,561.40	68,908
9/16/2025	David O. Watson	General Counsel	Sell	5,000	$24.34	$121,700.00	118,730
9/15/2025	James George Chopas	CAO	Sell	189	$24.19	$4,571.91	53,468
9/2/2025	James George Chopas	CAO	Sell	548	$28.08	$15,387.84	53,657
8/28/2025	Cedric Francois	CEO	Sell	49,963	$28.39	$1,418,449.57	307,946
8/27/2025	Cedric Francois	CEO	Sell	175,037	$28.19	$4,934,293.03	357,909
8/18/2025	David O. Watson	General Counsel	Sell	5,000	$27.80	$139,000.00	123,730
7/17/2025	Cedric Francois	CEO	Sell	19,725	$20.21	$398,642.25	331,605
7/16/2025	David O. Watson	General Counsel	Sell	5,000	$19.55	$97,750.00	128,730
7/15/2025	Cedric Francois	CEO	Sell	1,900	$20.09	$38,171.00	342,333
7/14/2025	Cedric Francois	CEO	Sell	137,465	$20.19	$2,775,418.35	343,433
6/16/2025	David O. Watson	General Counsel	Sell	5,000	$18.77	$93,850.00	133,730
3/17/2025	James George Chopas	CAO	Sell	183	$24.82	$4,542.06	47,955
3/5/2025	David O. Watson	General Counsel	Sell	5,569	$25.10	$139,781.90	138,730
2/11/2025	Mark Jeffrey DeLong	Insider	Sell	363	$28.54	$10,360.02	83,945
1/29/2025	Cedric Francois	CEO	Sell	2,824	$29.52	$83,364.48	415,695
1/29/2025	David O. Watson	General Counsel	Sell	695	$29.52	$20,516.40	144,299
1/29/2025	Nur Nicholson	Insider	Sell	825	$29.52	$24,354.00	83,664
1/29/2025	Timothy Eugene Sullivan	CFO	Sell	546	$29.52	$16,117.92	128,665
1/22/2025	Cedric Francois	CEO	Sell	13,551	$30.43	$412,356.93	418,519
1/22/2025	David O. Watson	General Counsel	Sell	3,323	$30.43	$101,118.89	144,994
1/22/2025	James George Chopas	CAO	Sell	1,096	$30.43	$33,351.28	48,138
1/22/2025	Nur Nicholson	Insider	Sell	3,948	$30.43	$120,137.64	84,489
1/22/2025	Timothy Eugene Sullivan	CFO	Sell	3,088	$30.43	$93,967.84	129,211
1/17/2025	Cedric Francois	CEO	Sell	6,007	$29.96	$179,969.72	301,408
1/17/2025	David O. Watson	General Counsel	Sell	2,201	$29.96	$65,941.96	105,555
1/17/2025	James George Chopas	CAO	Sell	715	$29.96	$21,421.40	36,643
1/17/2025	Nur Nicholson	Insider	Sell	2,145	$29.96	$64,264.20	52,011
1/17/2025	Timothy Eugene Sullivan	CFO	Sell	1,730	$29.96	$51,830.80	86,370
1/13/2025	Cedric Francois	CEO	Sell	6,247	$28.70	$179,288.90	307,415
1/13/2025	David O. Watson	General Counsel	Sell	4,965	$28.70	$142,495.50	107,756
1/13/2025	James George Chopas	CAO	Sell	783	$28.70	$22,472.10	37,358
1/13/2025	Jeffrey Eisele	Insider	Sell	264	$28.70	$7,576.80	56,881
1/13/2025	Timothy Eugene Sullivan	CFO	Sell	2,170	$28.70	$62,279.00	88,100
1/6/2025	Caroline Baumal	Insider	Sell	2,816	$33.81	$95,208.96	55,560
12/23/2024	Jeffrey Eisele	Insider	Sell	63	$33.09	$2,084.67	57,145
9/16/2024	A. Sinclair Dunlop	Director	Sell	37,000	$36.23	$1,340,510.00	100,000
6/21/2024	A. Sinclair Dunlop	Director	Sell	37,000	$39.24	$1,451,880.00	136,998
5/8/2024	Pascal Deschatelets	Insider	Sell	78,907	$42.35	$3,341,711.45	1,115,983
4/8/2024	Pascal Deschatelets	Insider	Sell	69,107	$54.17	$3,743,526.19	1,115,983
4/1/2024	Timothy Eugene Sullivan	CFO	Sell	4,000	$58.66	$234,640.00	93,338
3/19/2024	A. Sinclair Dunlop	Director	Sell	18,681	$57.18	$1,068,179.58	173,998
3/18/2024	Mark Jeffrey DeLong	Insider	Sell	9,913	$56.90	$564,049.70	54,693
3/15/2024	James George Chopas	CAO	Sell	184	$56.46	$10,388.64	38,883
3/13/2024	Nur Nicholson	Insider	Sell	11,220	$57.56	$645,823.20	56,287
3/1/2024	Cedric Francois	CEO	Sell	250,000	$64.11	$16,027,500.00	313,662
3/1/2024	Timothy Eugene Sullivan	CFO	Sell	6,000	$63.22	$379,320.00	93,338
2/12/2024	Adam J. Townsend	Insider	Sell	1,148	$67.77	$77,799.96	92,453
2/12/2024	Cedric Francois	CEO	Sell	3,962	$67.77	$268,504.74	313,662
2/12/2024	David O. Watson	General Counsel	Sell	781	$67.77	$52,928.37	103,390
2/12/2024	Timothy Eugene Sullivan	CFO	Sell	1,431	$67.77	$96,978.87	93,338
1/29/2024	Cedric Francois	CEO	Sell	2,843	$64.14	$182,350.02	317,624
1/29/2024	David O. Watson	General Counsel	Sell	906	$64.14	$58,110.84	104,171
1/29/2024	Nur Nicholson	Insider	Sell	835	$64.14	$53,556.90	67,507
1/22/2024	Adam J. Townsend	Insider	Sell	3,413	$65.00	$221,845.00	94,507
1/22/2024	Cedric Francois	CEO	Sell	13,431	$65.00	$873,015.00	320,467
1/22/2024	David O. Watson	General Counsel	Sell	4,184	$65.00	$271,960.00	105,077
1/22/2024	James George Chopas	CAO	Sell	1,061	$65.00	$68,965.00	39,067
1/22/2024	Timothy Eugene Sullivan	CFO	Sell	3,551	$65.00	$230,815.00	95,675
1/16/2024	Cedric Francois	CEO	Sell	7,851	$66.81	$524,525.31	333,898
1/16/2024	David O. Watson	General Counsel	Sell	4,240	$66.81	$283,274.40	109,261
1/16/2024	James George Chopas	CAO	Sell	864	$66.81	$57,723.84	40,128
1/16/2024	Jeffrey Eisele	Insider	Sell	438	$66.81	$29,262.78	72,650
1/16/2024	Timothy Eugene Sullivan	CFO	Sell	2,235	$66.81	$149,320.35	99,226
1/4/2024	Caroline Baumal	Insider	Sell	2,751	$60.05	$165,197.55	32,931
12/26/2023	Jeffrey Eisele	Insider	Sell	68	$57.86	$3,934.48	53,815
12/19/2023	David O. Watson	General Counsel	Sell	3,905	$57.23	$223,483.15	89,753
12/1/2023	Lukas Scheibler	Insider	Sell	10,000	$60.00	$600,000.00	68,299
11/21/2023	Cedric Francois	CEO	Sell	5,000	$48.80	$244,000.00	269,655
11/17/2023	Alec Machiels	Director	Sell	1,250	$47.74	$59,675.00	367,420
11/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$47.27	$567,240.00	1,071,807
10/23/2023	James George Chopas	CAO	Sell	132	$46.04	$6,077.28	32,680
10/23/2023	Mark Jeffrey DeLong	Insider	Sell	131	$46.04	$6,031.24	51,622
10/17/2023	Alec Machiels	Director	Sell	1,250	$48.50	$60,625.00	367,420
10/9/2023	Pascal Deschatelets	Insider	Sell	12,000	$40.38	$484,560.00	1,066,313
9/18/2023	Alec Machiels	Director	Sell	1,250	$45.00	$56,250.00	367,420
9/18/2023	Nur Nicholson	Insider	Sell	20,350	$44.27	$900,894.50	53,284
9/15/2023	Alec Machiels	Director	Sell	1,250	$45.34	$56,675.00	367,420
9/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$42.87	$514,440.00	1,059,813
9/1/2023	Cedric Francois	CEO	Sell	150,000	$41.75	$6,262,500.00	424,655
8/31/2023	James George Chopas	CAO	Sell	551	$41.23	$22,717.73	30,312
8/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$23.66	$283,920.00	1,053,313
7/17/2023	Alec Machiels	Director	Sell	1,250	$64.79	$80,987.50	267,641
7/10/2023	Pascal Deschatelets	Insider	Sell	12,000	$84.55	$1,014,600.00	1,046,813
7/3/2023	David O. Watson	General Counsel	Sell	8,510	$89.98	$765,729.80	85,753
7/3/2023	Timothy Eugene Sullivan	CFO	Sell	6,779	$89.97	$609,906.63	77,713
6/20/2023	Alec Machiels	Director	Sell	1,250	$88.41	$110,512.50	267,641
6/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$91.35	$1,096,200.00	1,040,313
6/5/2023	Timothy Eugene Sullivan	CFO	Sell	69,779	$88.80	$6,196,375.20	77,713
6/1/2023	Karen Lewis	Insider	Sell	5,000	$86.00	$430,000.00	41,504
5/17/2023	Alec Machiels	Director	Sell	1,250	$88.66	$110,825.00	267,641
5/16/2023	Cedric Francois	CEO	Sell	30,000	$85.66	$2,569,800.00	274,655
5/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$92.39	$1,108,680.00	1,033,813
5/3/2023	Adam J. Townsend	Insider	Sell	5,000	$82.71	$413,550.00	75,995
4/18/2023	Cedric Francois	CEO	Sell	30,000	$82.02	$2,460,600.00	637,601
4/17/2023	Alec Machiels	Director	Sell	1,250	$81.05	$101,312.50	267,641
4/10/2023	Pascal Deschatelets	Insider	Sell	12,000	$78.21	$938,520.00	1,027,313
4/3/2023	A. Sinclair Dunlop	Director	Sell	500	$74.05	$37,025.00	131,297
4/3/2023	Karen Lewis	Insider	Sell	5,000	$75.00	$375,000.00	41,430
3/21/2023	Cedric Francois	CEO	Sell	30,000	$62.74	$1,882,200.00	1,144,591
3/17/2023	Alec Machiels	Director	Sell	1,250	$64.03	$80,037.50	267,641
3/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$63.79	$765,480.00	1,020,813
2/23/2023	Jeffrey Eisele	Insider	Sell	1,646	$68.76	$113,178.96	53,883
2/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$54.45	$653,400.00	1,006,756
2/3/2023	Adam J. Townsend	Insider	Sell	5,000	$55.85	$279,250.00	67,932

SEC Filings (Institutional Ownership Changes) for Apellis Pharmaceuticals (NASDAQ:APLS)

96.29% of Apellis Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Apellis Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
1/30/2026	Jennison Associates LLC	1,504,299	$37.79M	0.0%	-65.4%	1.189%
1/30/2026	State of New Jersey Common Pension Fund D	25,863	$0.65M	0.0%	N/A	0.020%
1/30/2026	M&T Bank Corp	14,477	$0.36M	0.0%	+11.1%	0.011%
1/29/2026	Pictet Asset Management Holding SA	390,884	$9.84M	0.0%	+7.5%	0.309%
1/29/2026	UBS Group AG	4,186,222	$105.16M	0.0%	+22.1%	3.308%
1/29/2026	Vanguard Group Inc.	10,674,865	$268.15M	0.0%	+6.9%	8.437%
1/29/2026	China Universal Asset Management Co. Ltd.	20,617	$0.52M	0.0%	-6.9%	0.016%
1/28/2026	Arizona State Retirement System	21,010	$0.53M	0.0%	-5.8%	0.017%
1/28/2026	M&T Bank Corp	55,066	$1.38M	0.0%	+322.8%	0.044%
1/28/2026	Universal Beteiligungs und Servicegesellschaft mbH	95,755	$2.41M	0.0%	+107.7%	0.076%
1/27/2026	Zurcher Kantonalbank Zurich Cantonalbank	25,364	$0.64M	0.0%	+19.0%	0.020%
1/26/2026	Mirae Asset Global Investments Co. Ltd.	6,148	$0.15M	0.0%	+25.9%	0.005%
1/26/2026	CWM LLC	41,880	$1.05M	0.0%	-55.6%	0.033%
1/14/2026	Hennion & Walsh Asset Management Inc.	51,933	$1.31M	0.0%	+7.9%	0.041%
1/14/2026	Pallas Capital Advisors LLC	13,885	$0.35M	0.0%	-58.0%	0.011%
1/9/2026	SG Americas Securities LLC	567,046	$14.24M	0.0%	+35.9%	0.448%
1/9/2026	Diversified Trust Co.	18,942	$0.48M	0.0%	N/A	0.015%
1/8/2026	Wealth Enhancement Advisory Services LLC	30,175	$0.72M	0.0%	-61.1%	0.024%
1/8/2026	Wedmont Private Capital	11,883	$0.32M	0.0%	+4.1%	0.009%
1/1/2026	JPMorgan Chase & Co.	53,516	$1.21M	0.0%	-77.2%	0.042%
12/15/2025	Hudson Bay Capital Management LP	418,500	$9.47M	0.0%	-11.9%	0.331%
12/2/2025	Allworth Financial LP	2,194	$50K	0.0%	+64.1%	0.002%
11/21/2025	CIBC Bancorp USA Inc.	67,737	$1.53M	0.0%	N/A	0.054%
11/17/2025	CANADA LIFE ASSURANCE Co	17,747	$0.40M	0.0%	+186.8%	0.014%
11/17/2025	Caxton Associates LLP	10,969	$0.25M	0.0%	N/A	0.009%
11/17/2025	Woodline Partners LP	542,981	$12.29M	0.1%	+2.3%	0.429%
11/17/2025	PharVision Advisers LLC	22,291	$0.50M	0.3%	N/A	0.018%
11/17/2025	Voleon Capital Management LP	32,221	$0.73M	0.0%	-25.3%	0.025%
11/17/2025	Voloridge Investment Management LLC	992,269	$22.46M	0.1%	+111.7%	0.784%
11/17/2025	Scientech Research LLC	34,182	$0.77M	0.3%	N/A	0.027%
11/17/2025	Polar Capital Holdings Plc	2,650,230	$59.98M	0.3%	+96.0%	2.095%
11/17/2025	Quarry LP	16,022	$0.36M	0.1%	+220.4%	0.013%
11/17/2025	Qube Research & Technologies Ltd	120,003	$2.72M	0.0%	N/A	0.095%
11/17/2025	Mariner LLC	43,239	$0.98M	0.0%	+19.0%	0.034%
11/17/2025	Mercer Global Advisors Inc. ADV	39,043	$0.88M	0.0%	+86.4%	0.031%
11/17/2025	Millennium Management LLC	1,343,726	$30.41M	0.0%	+563.7%	1.062%
11/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	8,609	$0.20M	0.0%	-79.0%	0.007%
11/17/2025	Integrated Wealth Concepts LLC	10,190	$0.23M	0.0%	-19.0%	0.008%
11/17/2025	HighVista Strategies LLC	145,729	$3.30M	0.8%	+68.2%	0.115%
11/17/2025	Gotham Asset Management LLC	127,158	$2.88M	0.0%	+6.7%	0.100%
11/17/2025	Focus Partners Wealth	21,771	$0.49M	0.0%	-26.6%	0.017%
11/17/2025	Brevan Howard Capital Management LP	91,021	$2.06M	0.0%	N/A	0.072%
11/17/2025	California Public Employees Retirement System	146,188	$3.31M	0.0%	+8.6%	0.116%
11/17/2025	Bank of America Corp DE	1,477,525	$33.44M	0.0%	-39.1%	1.168%
11/17/2025	Bank of Nova Scotia	1,456,225	$32.95M	0.1%	+144.8%	1.151%
11/17/2025	Aquatic Capital Management LLC	130,828	$2.96M	0.1%	-26.0%	0.103%
11/17/2025	Algert Global LLC	109,733	$2.48M	0.0%	-28.8%	0.087%
11/17/2025	Alliancebernstein L.P.	80,605	$1.82M	0.0%	+152.5%	0.064%
11/17/2025	Ameriprise Financial Inc.	717,703	$16.24M	0.0%	-4.3%	0.567%
11/14/2025	Schonfeld Strategic Advisors LLC	47,282	$1.07M	0.0%	-43.7%	0.037%
11/14/2025	Creative Planning	35,645	$0.81M	0.0%	+63.2%	0.028%
11/14/2025	AQR Capital Management LLC	4,487,354	$101.55M	0.1%	-24.9%	3.546%
11/14/2025	Raymond James Financial Inc.	77,678	$1.76M	0.0%	+4.3%	0.061%
11/14/2025	Amundi	1,493,678	$36.39M	0.0%	-6.9%	1.180%
11/14/2025	Deep Track Capital LP	8,000,382	$181.05M	5.1%	+14.3%	6.323%
11/14/2025	Man Group plc	67,202	$1.52M	0.0%	N/A	0.053%
11/14/2025	California State Teachers Retirement System	73,298	$1.66M	0.0%	-16.6%	0.058%
11/14/2025	ADAR1 Capital Management LLC	20,000	$0.45M	0.0%	+17.6%	0.016%
11/14/2025	Zurcher Kantonalbank Zurich Cantonalbank	21,317	$0.48M	0.0%	+11.4%	0.017%
11/14/2025	Fiduciary Trust Co	198,179	$4.49M	0.1%	-2.2%	0.157%
11/14/2025	UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC	167,464	$3.79M	0.0%	-44.5%	0.132%
11/14/2025	Two Sigma Investments LP	252,068	$5.70M	0.0%	-38.1%	0.199%
11/14/2025	Vident Advisory LLC	35,381	$0.80M	0.0%	N/A	0.028%
11/14/2025	Concentric Capital Strategies LP	17,979	$0.41M	0.0%	N/A	0.014%
11/14/2025	Integral Health Asset Management LLC	250,000	$5.66M	0.4%	N/A	0.198%
11/13/2025	Jump Financial LLC	277,648	$6.28M	0.1%	-50.3%	0.219%
11/13/2025	Marshall Wace LLP	396,735	$8.98M	0.0%	-85.3%	0.314%
11/13/2025	Stelac Advisory Services LLC	5,520	$0.13M	0.0%	N/A	0.004%
11/13/2025	Entropy Technologies LP	24,603	$0.56M	0.0%	N/A	0.019%
11/13/2025	Landscape Capital Management L.L.C.	75,000	$1.70M	0.1%	+16.2%	0.059%
11/13/2025	Invesco Ltd.	183,016	$4.14M	0.0%	+10.2%	0.145%
11/13/2025	Sei Investments Co.	155,122	$3.51M	0.0%	+593.8%	0.123%
11/13/2025	UBS Group AG	3,429,905	$77.62M	0.0%	-27.6%	2.711%
11/13/2025	BNP Paribas Financial Markets	972,474	$22.01M	0.0%	-25.1%	0.769%
11/13/2025	Mackenzie Financial Corp	76,711	$1.74M	0.0%	+3.4%	0.061%
11/13/2025	Legal & General Group Plc	92,392	$2.09M	0.0%	-3.8%	0.073%
11/13/2025	Swiss National Bank	146,200	$3.31M	0.0%	+1.7%	0.116%
11/13/2025	Schroder Investment Management Group	173,087	$3.92M	0.0%	-64.4%	0.137%
11/13/2025	Rhenman & Partners Asset Management AB	232,250	$5.26M	0.6%	+149.1%	0.184%
11/12/2025	Barclays PLC	269,527	$6.10M	0.0%	-1.6%	0.213%
11/12/2025	Dimensional Fund Advisors LP	18,690	$0.42M	0.0%	N/A	0.015%
11/12/2025	Focus Partners Advisor Solutions LLC	19,919	$0.45M	0.0%	-18.2%	0.016%
11/12/2025	Rafferty Asset Management LLC	168,352	$3.81M	0.0%	+17.0%	0.133%
11/12/2025	Quantbot Technologies LP	2,813	$64K	0.0%	N/A	0.002%
11/12/2025	Erste Asset Management GmbH	25,300	$0.57M	0.0%	-39.8%	0.020%
11/12/2025	Handelsbanken Fonder AB	39,100	$0.89M	0.0%	+29.5%	0.031%
11/12/2025	Xponance Inc.	17,483	$0.40M	0.0%	-4.8%	0.014%
11/12/2025	Fox Run Management L.L.C.	27,223	$0.62M	0.1%	+94.9%	0.022%
11/10/2025	EverSource Wealth Advisors LLC	4,865	$0.11M	0.0%	-10.4%	0.004%
11/10/2025	Clearstead Advisors LLC	1,719	$39K	0.0%	-44.7%	0.001%
11/10/2025	Bleakley Financial Group LLC	79,305	$1.80M	0.0%	+2.9%	0.063%
11/10/2025	China Universal Asset Management Co. Ltd.	22,137	$0.50M	0.0%	-12.3%	0.017%
11/7/2025	Readystate Asset Management LP	241,977	$5.48M	0.2%	N/A	0.191%
11/7/2025	GSA Capital Partners LLP	31,446	$0.71M	0.1%	N/A	0.025%
11/7/2025	Vanguard Group Inc.	9,987,394	$226.02M	0.0%	-1.6%	7.893%
11/7/2025	JPMorgan Chase & Co.	53,516	$1.21M	0.0%	-77.2%	0.042%
11/7/2025	PNC Financial Services Group Inc.	54,052	$1.22M	0.0%	-8.2%	0.043%
11/6/2025	ING Groep NV	1,174,500	$26.58M	0.1%	+281.0%	0.928%
11/6/2025	Rhumbline Advisers	117,429	$2.66M	0.0%	-3.7%	0.093%
11/6/2025	Profund Advisors LLC	34,712	$0.79M	0.0%	+21.0%	0.027%

Data available starting January 2016

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $23.32

$22.50

$23.93

50 Day Range

MA: $23.40

$19.94

$27.30

52 Week Range

Now: $23.32

$16.10

$30.60

Volume

2,647,208 shs

Average Volume

3,888,805 shs

Market Capitalization

$2.95 billion

P/E Ratio

75.23

Dividend Yield

N/A

Beta

0.26

Who are the company insiders with the largest holdings of Apellis Pharmaceuticals?: Apellis Pharmaceuticals' top insider investors include:
Pascal Deschatelets (Insider)
Cedric Francois (CEO)
A Sinclair Dunlop (Director)
David O Watson (General Counsel)
Timothy Eugene Sullivan (CFO)
Adam J Townsend (Insider)
Caroline Baumal (Insider)
Nur Nicholson (Insider)
Mark Jeffrey Delong (Insider)
Jeffrey Eisele (Insider)
James George Chopas (CAO)
Learn More about top insider investors at Apellis Pharmaceuticals.
Who are the major institutional investors of Apellis Pharmaceuticals?: Apellis Pharmaceuticals' top institutional shareholders include:
Vanguard Group Inc. — 8.44%
UBS Group AG — 3.31%
Jennison Associates LLC — 1.19%
SG Americas Securities LLC — 0.45%
Pictet Asset Management Holding SA — 0.31%
Universal Beteiligungs und Servicegesellschaft mbH — 0.08%
Learn More about top institutional investors of Apellis Pharmaceuticals stock.
Which institutional investors are selling Apellis Pharmaceuticals stock?: Within the last quarter, APLS stock was sold by these institutional investors:
Jennison Associates LLC
CWM LLC
Wealth Enhancement Advisory Services LLC
Pallas Capital Advisors LLC
China Universal Asset Management Co. Ltd.
Arizona State Retirement System
In the last year, company insiders that have sold Apellis Pharmaceuticals company stock include:
Pascal Deschatelets (Insider)
Cedric Francois (CEO)
A Sinclair Dunlop (Director)
David O Watson (General Counsel)
Timothy Eugene Sullivan (CFO)
Adam J Townsend (Insider)
Caroline Baumal (Insider)
Nur Nicholson (Insider)
Mark Jeffrey Delong (Insider)
Learn More investors selling Apellis Pharmaceuticals stock.
Which institutional investors are buying Apellis Pharmaceuticals stock?: During the previous quarter, APLS stock was purchased by institutional investors including:
UBS Group AG
Vanguard Group Inc.
SG Americas Securities LLC
Universal Beteiligungs und Servicegesellschaft mbH
M&T Bank Corp
Pictet Asset Management Holding SA
State of New Jersey Common Pension Fund D
Diversified Trust Co.